Income Statement Seelos Therapeutics, Inc.
Stocks
SEELQ
US81577F4063
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000100 USD | +9,900.00% |
|
0.00% | - |
| 12-28 | Motion for Asset Sale Approved for Seelos Therapeutics, Inc. | CI |
| 25-10-21 | GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q). | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
Revenues | 375K | - | - | - | 2.2M | |||
Total Revenues | 375K | - | - | - | 2.2M | |||
Cost of Goods Sold, Total | - | 10.98M | - | - | 30.12M | |||
Gross Profit | 375K | -10.98M | - | - | -27.91M | |||
Selling General & Admin Expenses, Total | 5.56M | 7.78M | 15.02M | 12.3M | 12.58M | |||
R&D Expenses | 22.56M | - | 46.65M | 58.62M | - | |||
Other Operating Expenses | - | - | - | - | - | |||
Other Operating Expenses, Total | 28.12M | 7.78M | 61.67M | 70.92M | 12.58M | |||
Operating Income | -27.75M | -18.76M | -61.67M | -70.92M | -40.5M | |||
Interest Expense, Total | -29K | -164K | -1.6M | -14K | -75K | |||
Interest And Investment Income | 151K | 45K | 113K | 121K | 198K | |||
Net Interest Expenses | 122K | -119K | -1.48M | 107K | 123K | |||
Other Non Operating Income (Expenses) | -21.52M | -223K | -886K | 292K | 13.69M | |||
EBT, Excl. Unusual Items | -49.15M | -19.1M | -64.04M | -70.52M | -26.68M | |||
Merger & Related Restructuring Charges | -2M | - | - | - | - | |||
Other Unusual Items | -109K | - | -2.01M | -3.02M | -11.2M | |||
EBT, Incl. Unusual Items | -51.26M | -19.1M | -66.05M | -73.53M | -37.88M | |||
Earnings From Continuing Operations | -51.26M | -19.1M | -66.05M | -73.53M | -37.88M | |||
Earnings Of Discontinued Operations | - | - | - | - | - | |||
Net Income to Company | -51.26M | -19.1M | -66.05M | -73.53M | -37.88M | |||
Net Income - (IS) | -51.26M | -19.1M | -66.05M | -73.53M | -37.88M | |||
Net Income to Common Incl Extra Items | -51.26M | -19.1M | -66.05M | -73.53M | -37.88M | |||
Net Income to Common Excl. Extra Items | -51.26M | -19.1M | -66.05M | -73.53M | -37.88M | |||
Per Share Items | ||||||||
Net EPS - Basic | - | -1.64K | -2.79K | -2.66K | -989.53 | |||
Basic EPS - Continuing Operations | - | -1.64K | -2.79K | -2.66K | -989.53 | |||
Basic Weighted Average Shares Outstanding | - | 11.66K | 23.67K | 27.69K | 38.28K | |||
Net EPS - Diluted | - | -1.64K | -2.79K | -2.66K | -989.53 | |||
Diluted EPS - Continuing Operations | - | -1.64K | -2.79K | -2.66K | -989.53 | |||
Diluted Weighted Average Shares Outstanding | - | 11.66K | 23.67K | 27.69K | 38.28K | |||
Normalized Basic EPS | - | -1.02K | -1.69K | -1.59K | -435.6 | |||
Normalized Diluted EPS | - | -1.02K | -1.69K | -1.59K | -435.6 | |||
Supplemental Items | ||||||||
EBITDA | -27.71M | - | - | - | - | |||
EBITA | -27.75M | -18.76M | -61.67M | -70.92M | -40.5M | |||
EBIT | -27.75M | -18.76M | -61.67M | -70.92M | -40.5M | |||
EBITDAR | -27.61M | - | - | - | - | |||
Total Revenues (As Reported) | 375K | - | - | - | 2.2M | |||
Normalized Net Income | -30.72M | -11.94M | -40.02M | -44.07M | -16.68M | |||
Interest on Long-Term Debt | - | - | 1.6M | 14K | 75K | |||
Supplemental Operating Expense Items | ||||||||
General and Administrative Expenses | 5.56M | 7.78M | 15.02M | 12.3M | 12.58M | |||
Research And Development Expense From Footnotes | 22.56M | 10.98M | 46.65M | 58.62M | 30.12M | |||
Net Rental Expense, Total | 100K | 100K | 100K | 100K | 100K | |||
Imputed Operating Lease Interest Expense | - | - | 89.14K | 573 | 3.49K | |||
Imputed Operating Lease Depreciation | - | - | 10.86K | 99.43K | 96.51K | |||
Stock-Based Comp., COGS (Total) | - | 394K | 717K | - | 1.04M | |||
Stock-Based Comp., R&D Exp. (Total) | 118K | - | - | 932K | - | |||
Stock-Based Comp., G&A Exp. (Total) | 341K | 1.65M | 7.63M | 4.14M | 2.95M | |||
Stock-Based Comp., Other (Total) | - | 124K | - | - | - | |||
Total Stock-Based Compensation | 459K | 2.17M | 8.35M | 5.07M | 3.99M |
- Stock Market
- Stocks
- SEELQ Stock
- Financials Seelos Therapeutics, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















